AAV-MP-135-EGFP

AAV-MP-135-EGFP series viruses are ready to use AAV vectors carrying MP-135-EGFP expression cassette, in which the EGFP reporter is droved by a MP-135 promoter. The AAV-MP-135-EGFP vectors are available with 16 different serotypes, and there are over 1000 AAV serotypes/variants to be choose for custom AAV packaging.
The MP-135 is a micro promoter derived from the promoter of human glucagon gene. Despite its small size (135 bp), it demonstrates activity comparable to the strong, ubiquitous CAG promoter across diverse cell types and tissues. MP-135 drives robust expression in both skeletal and cardiac muscle, making it particularly valuable for neuromuscular disease models and cardiac gene therapy. rAAV constructs containing MP-135 have also shown strong activity in cultured cells from all three germ-layer lineages, with reporter expression documented in human primary hepatocytes, pancreatic islets, and multiple mouse tissues in vivo, including brain and skeletal muscle. Its compact design conserves AAV packaging capacity, allowing more space for larger therapeutic payloads.
By employing EGFP as a reporter, researchers gain the ability to effortlessly visualize and quantify the transduction efficiency of AAV vectors within target cells, further enhancing the precision of their experiments.

Please contact us at for specific academic pricing.

Background

AAV viruses or AAV vectors, are a convenient solution for researchers who need to perform gene delivery experiments, such as gene therapy, gene editing, and gene regulation. The premade AAV viruses are available in various serotypes, promoters, and reporters/transgenes, allowing researchers to choose the most suitable vector for their specific research application. With over a thousand known AAV serotypes, customers have the tools to rapidly determine the vector specificity for various cell types. Additionally, the availability of multiple promoters paired with reporter genes allows for easy assessment and monitoring of gene expression levels and timing.

To ensure high-quality and pure products, various assays are used to assess the quality and purity of their AAV vectors:
· Gene specific qPCR Titer: Target the specific transgenes or common used elements, such as WPRE, CMV, PolyA, but not ITR.
· Full/Empty Particle Ratio: Ensure all the premade AAVs has >80% full particles by Mass Photometry.
· Endotoxin Testing: Ensure safety with endotoxin level <1U/1e13VG.
· SDS-PAGE Gel: Assess the purity of the AAV viruses is great than 95%.
· Infectivity Assay: Evaluate the efficiency of AAV viruses in transducing target cells if they have reporters.